Insider Buy/Sell Details for the Biotechnology Industry — Last 3 Months
Ratio0.1:1
Daily Buy & Sell Volume
Transactions (3480)
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
697
Price
$483.80
Total Value
$337.21K
Shares Held After
10,701
% of Holdings
6.1%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
873
Price
$482.72
Total Value
$421.41K
Shares Held After
11,398
% of Holdings
7.1%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
1,657
Price
$481.86
Total Value
$798.45K
Shares Held After
12,271
% of Holdings
11.9%
UNITED THERAPEUTICS Corp (UTHR)
BENKOWITZ MICHAEL — PRESIDENT AND COO
Shares
697
Price
$480.68
Total Value
$335.04K
Shares Held After
13,928
% of Holdings
4.8%
RECURSION PHARMACEUTICALS, INC. (RXRX)
Gibson Christopher — Director
Shares
40,000
Price
$4.25
Total Value
$170.00K
Shares Held After
933,839
% of Holdings
4.1%
Crinetics Pharmaceuticals, Inc. (CRNX)
Kalofonos Isabel — Chief Commercial Officer
Shares
2,500
Price
$55.00
Total Value
$137.50K
Shares Held After
834
% of Holdings
75.0%
Nuvalent, Inc. (NUVL)
Porter James Richard — Director
Shares
1,337
Price
$98.52
Total Value
$131.72K
Shares Held After
288,172
% of Holdings
0.5%
Nuvalent, Inc. (NUVL)
Porter James Richard — Director
Shares
8,147
Price
$97.96
Total Value
$798.08K
Shares Held After
289,509
% of Holdings
2.7%
Nuvalent, Inc. (NUVL)
Porter James Richard — Director
Shares
4,727
Price
$96.85
Total Value
$457.81K
Shares Held After
297,656
% of Holdings
1.6%
Nuvalent, Inc. (NUVL)
Balcom Alexandra — Chief Financial Officer
Shares
317
Price
$98.52
Total Value
$31.23K
Shares Held After
84,914
% of Holdings
0.4%
Nuvalent, Inc. (NUVL)
Balcom Alexandra — Chief Financial Officer
Shares
1,929
Price
$97.96
Total Value
$188.96K
Shares Held After
85,231
% of Holdings
2.2%
Nuvalent, Inc. (NUVL)
Balcom Alexandra — Chief Financial Officer
Shares
1,119
Price
$96.85
Total Value
$108.38K
Shares Held After
87,160
% of Holdings
1.3%
Nuvalent, Inc. (NUVL)
Turner Christopher Durant — Chief Medical Officer
Shares
317
Price
$98.52
Total Value
$31.23K
Shares Held After
58,311
% of Holdings
0.5%
Nuvalent, Inc. (NUVL)
Turner Christopher Durant — Chief Medical Officer
Shares
1,929
Price
$97.96
Total Value
$188.96K
Shares Held After
58,628
% of Holdings
3.2%
Nuvalent, Inc. (NUVL)
Turner Christopher Durant — Chief Medical Officer
Shares
1,119
Price
$96.85
Total Value
$108.38K
Shares Held After
60,557
% of Holdings
1.8%
Nuvalent, Inc. (NUVL)
Miller Deborah Ann — Chief Legal Officer
Shares
326
Price
$98.52
Total Value
$32.12K
Shares Held After
44,723
% of Holdings
0.7%
Nuvalent, Inc. (NUVL)
Miller Deborah Ann — Chief Legal Officer
Shares
1,987
Price
$97.96
Total Value
$194.65K
Shares Held After
45,049
% of Holdings
4.2%
Nuvalent, Inc. (NUVL)
Miller Deborah Ann — Chief Legal Officer
Shares
1,153
Price
$96.85
Total Value
$111.67K
Shares Held After
47,036
% of Holdings
2.4%
Nuvalent, Inc. (NUVL)
Noci Darlene — Chief Development Officer
Shares
317
Price
$98.52
Total Value
$31.23K
Shares Held After
43,798
% of Holdings
0.7%
Nuvalent, Inc. (NUVL)
Noci Darlene — Chief Development Officer
Shares
1,929
Price
$97.96
Total Value
$188.96K
Shares Held After
44,115
% of Holdings
4.2%
Nuvalent, Inc. (NUVL)
Noci Darlene — Chief Development Officer
Shares
1,119
Price
$96.85
Total Value
$108.38K
Shares Held After
46,044
% of Holdings
2.4%
Nuvalent, Inc. (NUVL)
Pelish Henry E. — Chief Scientific Officer
Shares
186
Price
$98.52
Total Value
$18.32K
Shares Held After
68,552
% of Holdings
0.3%
Nuvalent, Inc. (NUVL)
Pelish Henry E. — Chief Scientific Officer
Shares
1,137
Price
$97.96
Total Value
$111.38K
Shares Held After
68,738
% of Holdings
1.6%
Nuvalent, Inc. (NUVL)
Pelish Henry E. — Chief Scientific Officer
Shares
660
Price
$96.85
Total Value
$63.92K
Shares Held After
69,875
% of Holdings
0.9%
Axsome Therapeutics, Inc. (AXSM)
TABUTEAU HERRIOT — Director
Shares
78,703
Price
$171.28
Total Value
$13.48M
Shares Held After
7,229
% of Holdings
91.6%
Acumen Pharmaceuticals, Inc. (ABOS)
Siemers Eric — Chief Medical Officer
Shares
4,000
Price
$1.96
Total Value
$7.83K
Shares Held After
166,298
% of Holdings
2.3%
Acumen Pharmaceuticals, Inc. (ABOS)
OConnell Daniel Joseph — Director
Shares
4,649
Price
$1.97
Total Value
$9.16K
Shares Held After
662,839
% of Holdings
0.7%
Acumen Pharmaceuticals, Inc. (ABOS)
Meisner Derek M — Chief Legal Officer & Corp Sec
Shares
4,000
Price
$1.96
Total Value
$7.84K
Shares Held After
157,127
% of Holdings
2.5%
Acumen Pharmaceuticals, Inc. (ABOS)
Zuga Matt — CFO & Chief Business Officer
Shares
4,000
Price
$1.96
Total Value
$7.84K
Shares Held After
227,744
% of Holdings
1.7%
Acumen Pharmaceuticals, Inc. (ABOS)
Barton Russell — Chief Operating Officer
Shares
4,000
Price
$1.96
Total Value
$7.83K
Shares Held After
132,117
% of Holdings
2.9%
Adaptive Biotechnologies Corp (ADPT)
ROBINS CHAD M — Director
Shares
124,998
Price
$15.59
Total Value
$1.95M
Shares Held After
2,584,243
% of Holdings
4.6%
AN2 Therapeutics, Inc. (ANTX)
Eizen Joshua M — Chief Operating Officer and Chief Legal Officer
Shares
17,923
Price
$1.00
Total Value
$17.95K
Shares Held After
159,430
% of Holdings
10.1%
AN2 Therapeutics, Inc. (ANTX)
Chanda Sanjay — Chief Development Officer
Shares
3,295
Price
$1.00
Total Value
$3.30K
Shares Held After
81,779
% of Holdings
3.9%
AN2 Therapeutics, Inc. (ANTX)
Prior Stephen David — Chief Strategy Officer
Shares
3,604
Price
$1.00
Total Value
$3.61K
Shares Held After
61,944
% of Holdings
5.5%
AN2 Therapeutics, Inc. (ANTX)
Day Lucy — Chief Financial Officer
Shares
3,295
Price
$1.00
Total Value
$3.30K
Shares Held After
80,875
% of Holdings
3.9%
NewAmsterdam Pharma Co N.V. (NAMS)
Kastelein Johannes Jacob Pieter — Director
Shares
6,000
Price
$33.25
Total Value
$199.50K
Shares Held After
73,481
% of Holdings
7.5%
NewAmsterdam Pharma Co N.V. (NAMS)
Kooij Louise Frederika — Chief Accounting Officer
Shares
2,647
Price
$33.25
Total Value
$88.01K
Shares Held After
12,353
% of Holdings
17.6%
NewAmsterdam Pharma Co N.V. (NAMS)
Somaiya Mayur Ian — Chief Financial Officer
Shares
5,118
Price
$33.25
Total Value
$170.17K
Shares Held After
32,882
% of Holdings
13.5%
PharmaCyte Biotech, Inc. (PMCB)
Silverman Joshua — Director
Shares
30,000
Price
$0.78
Total Value
$23.49K
Shares Held After
346,250
% of Holdings
8.7%
Arcutis Biotherapeutics, Inc. (ARQT)
Burnett Patrick — Reporting Person's Title: Executive Vice President and Chief Medical Officer
Shares
2,490
Price
$28.98
Total Value
$72.17K
Shares Held After
94,120
% of Holdings
2.6%
PharmaCyte Biotech, Inc. (PMCB)
SCHECHTER JONATHAN — Director
Shares
20,000
Price
$0.78
Total Value
$15.55K
Shares Held After
152,500
% of Holdings
13.1%
Nuvalent, Inc. (NUVL)
Noci Darlene — Chief Development Officer
Shares
871
Price
$96.06
Total Value
$83.67K
Shares Held After
47,163
% of Holdings
1.8%
Clene Inc. (CLNN)
Ugwumba Chidozie — 10% Owner
Shares
5,869
Price
$5.87
Total Value
$34.45K
Shares Held After
760,611
% of Holdings
0.8%
Nuvalent, Inc. (NUVL)
Porter James Richard — Director
Shares
3,679
Price
$96.06
Total Value
$353.40K
Shares Held After
302,383
% of Holdings
1.2%
Nuvalent, Inc. (NUVL)
Turner Christopher Durant — Chief Medical Officer
Shares
871
Price
$96.06
Total Value
$83.67K
Shares Held After
61,676
% of Holdings
1.4%
Nuvalent, Inc. (NUVL)
Pelish Henry E. — Chief Scientific Officer
Shares
513
Price
$96.06
Total Value
$49.28K
Shares Held After
70,535
% of Holdings
0.7%
Werewolf Therapeutics, Inc. (HOWL)
EVNIN LUKE — Director
Shares
18,378
Price
$0.64
Total Value
$11.76K
Shares Held After
2,453,919
% of Holdings
0.7%
Nuvalent, Inc. (NUVL)
Miller Deborah Ann — Chief Legal Officer
Shares
897
Price
$96.06
Total Value
$86.17K
Shares Held After
48,189
% of Holdings
1.8%
Nuvalent, Inc. (NUVL)
Balcom Alexandra — Chief Financial Officer
Shares
871
Price
$96.06
Total Value
$83.67K
Shares Held After
88,279
% of Holdings
1.0%
Climb Bio, Inc. (CLYM)
RA CAPITAL MANAGEMENT, L.P. — Director
Shares
7,111
Price
$3.50
Total Value
$24.89K
Shares Held After
3,403,429
% of Holdings
0.2%
Showing 3051–3100 of 3480 transactions (page 62 of 70)